CN115261355B - AMPK alpha 1 succinylation modification and application - Google Patents

AMPK alpha 1 succinylation modification and application Download PDF

Info

Publication number
CN115261355B
CN115261355B CN202211116713.5A CN202211116713A CN115261355B CN 115261355 B CN115261355 B CN 115261355B CN 202211116713 A CN202211116713 A CN 202211116713A CN 115261355 B CN115261355 B CN 115261355B
Authority
CN
China
Prior art keywords
lung cancer
succinylation
ampk alpha
ampk
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202211116713.5A
Other languages
Chinese (zh)
Other versions
CN115261355A (en
Inventor
伍俊
张海涛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Medical University
Original Assignee
Guangdong Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guangdong Medical University filed Critical Guangdong Medical University
Priority to CN202211116713.5A priority Critical patent/CN115261355B/en
Publication of CN115261355A publication Critical patent/CN115261355A/en
Application granted granted Critical
Publication of CN115261355B publication Critical patent/CN115261355B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0688—Cells from the lungs or the respiratory tract
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/11—Protein-serine/threonine kinases (2.7.11)
    • C12Y207/11031—[Hydroxymethylglutaryl-CoA reductase (NADPH)] kinase (2.7.11.31)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
    • G01N2440/10—Post-translational modifications [PTMs] in chemical analysis of biological material acylation, e.g. acetylation, formylation, lipoylation, myristoylation, palmitoylation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The invention discloses an AIF1 succinylation modification and application, wherein the succinylation modification of the 266 th site lysine residue of AMPK alpha 1 is obviously higher than that of paracancerous tissues, the biological functions of the AMPKA1 are affected, the effects of promoting and maintaining the survival and growth of lung cancer cells are achieved, and the succinylation level change of the AMPK alpha 1 can be used as a marker and a target point for the occurrence and development of lung cancer.

Description

AMPK alpha 1 succinylation modification and application
Technical Field
The invention relates to the technical field of biomedicine. In particular to AMPK alpha 1 succinylation modification and application.
Background
Adenylate-activated protein kinase α1 (adenosine activated proteinkinase, AMPK) is allosterically activated by adenosine monophosphate and is a trimer composed of α, β, γ subunits, including α1 and α2 subtype, β subunits including β1 and β2, γ subunits including γ1, γ2 and γ3, wherein the α subunits play a catalytic role in determining the activity of the protein kinase complex, whereas the β and γ subunits play an important role in maintaining trimer stability and substrate specificity, and AMP/ADP, AMPK upstream kinase (liver kinase B1 (LKB 1), transforming growth factor β -activated protein kinase 1 (TAK 1) and calcium/calmodulin dependent protein kinase- β (CaMKK- β)) in the organism can activate AMPK directly or indirectly; in addition, the surface DNA damage can also activate AMPK, and the AMPK can influence the growth of NSCLC cells through the regulation of autophagy and apoptosis, the regulation of carbohydrate metabolism, the regulation of lipid metabolism, the regulation of protein metabolism and the regulation of mitochondrial function under different environments.
Lung cancer is a malignant tumor with the greatest harm to human health and life in the world today, although research on lung cancer is continuously explored by researchers, the occurrence and development mechanism of lung cancer is still not completely clear, and with the continuous deep research on cancer, researchers find that the change of covalent modification after translation of cancer cell proteins has a very close relationship with the development of carcinogenesis, which suggests that the mechanism of covalent modification and transformation after translation of cancer cell proteins may become one of important break-through for preventing and treating cancer.
The succinylation modification is capable of regulating gene expression and various metabolic processes, and abnormality thereof is closely related to occurrence and development of various diseases including tumor, heart metabolic disease, liver metabolic disease, nervous system disease and the like, and is known to be related to various malignant tumors including intestinal cancer, lung cancer, skin melanoma, hepatocellular carcinoma, osteosarcoma, nervous system malignant tumor, renal cell carcinoma, thyroid cancer, colon cancer and the like, and whether or not there is succinylation site of AMPK alpha 1, influence of succinylation site on biological function of AMPK alpha 1 and relationship with occurrence and development of lung cancer are not known in the prior art.
Disclosure of Invention
Therefore, the technical problem to be solved by the invention is to provide AMPK alpha 1 succinylation modification and application, wherein AMPK alpha 1 is succinylated at a 266 th site lysine residue (K266), has the effect of promoting and maintaining the survival and growth of lung cancer cells, and the succinylation level change can be used as a marker and a target point for the occurrence and development of lung cancer.
In order to solve the technical problems, the invention provides the following technical scheme:
AMPKα1 succinylation modification, AMPKα1 succinylation modification of lysine residue at position 266.
Application of AMPK alpha 1 in 266 th site lysine residue succinylation modification as a marker and target of occurrence and development of lung cancer.
Application of AMPK alpha 1 in preparing preparation for promoting growth, proliferation and/or migration of tumor cells or cancer cells by succinylation modification of lysine residue at 266 th site.
Further, the tumor cell or cancer cell is a lung cancer cell.
Application of AMPK alpha 1 in preparing antitumor drugs by succinylation modification of 266 th site lysine residue.
Application of AMPK alpha 1 in preparing cancer diagnosis reagent or kit by succinylation modification of 266 th site lysine residue.
Further, the cancer is lung cancer.
Application of AMPK alpha 1 in preparing lung cancer cell sample by succinylation modification of lysine residue at 266 th site.
Application of AMPK alpha 1 in preparing reagent or kit for verifying succinylation of AMPK alpha 1 by succinylation modification of lysine residue at 266 th site.
A product, the active ingredient of which comprises succinylation modification of AMPK α1 at lysine residue 266, said product having at least one of the following functions (1) to (5):
(1) Predicting the risk of occurrence and development progression of lung cancer; (2) an increase in the number of cells predicted to have lung cancer, poor prognosis; (3) promoting and maintaining lung cancer cell survival and growth; (4) as a target for treating lung cancer; (5) serving as a drug target for treating lung cancer. .
The technical scheme of the invention has the following beneficial technical effects:
the succinylation of AMPK alpha 1 at 266 th site lysine residue (K266) remarkably increases the growth of lung cancer A549 cells, can predict the risk of occurrence and development progress of lung cancer, can be used as a target point for treating lung cancer, can be further applied to the prevention and the prognosis of other tumor cells, provides a new diagnosis method for diagnosing lung cancer clinically at molecular level, and provides a new drug target point for treating lung cancer
Drawings
FIG. 1 is a schematic diagram of the expression level of the AMPKα1 modified by the succinylation of AMPKα1 and K266 succinylation applied to the modification;
FIG. 2 is a schematic diagram showing correlation between AMPK alpha 1 succinylation modification and applied AMPK alpha 1 succinylation level and prognosis of the present invention;
in fig. 2, number at risk indicates the Number of people who have not occurred an endpoint event in the Time node corresponding to Time;
FIG. 3 is a schematic diagram showing the effect of the AMPK alpha 1 succinylation modification and the applied K266 succinylation modification AMPK alpha 1 on lung cancer growth;
in fig. 3: A. tumor mass volume; B. tumor mass weight: p is less than 0.01;
wild type AIF1: lung cancer cells expressing AMPK α1;
k266 succinylation modification ampkα1: a lung cancer cell expressing lysine 266 th succinylated modified AMPK alpha 1.
Detailed Description
Example 1
In view of the fact that the succinylation modification of AMPK alpha 1 has not been disclosed yet, the embodiment provides a novel mode of succinylation modification of AMPK alpha 1, namely, the succinylation of AMPK alpha 1 at the 266 th site lysine residue K66, the 266 th site lysine of wild AMPK alpha 1 is mutated into glutamic acid to simulate succinylated AMPK alpha 1, the succinylation level of AMPK alpha 1 in K66 of clinical specimen lung cancer tissue is analyzed by immunohistochemistry, and the result shows that the succinylated simulated AMPK alpha 1 remarkably increases the growth of lung cancer A549 cells inoculated in nude mice, so that the 266 th site lysine succinylated AMPK alpha 1 has the effect of promoting and maintaining the survival and growth of lung cancer cells, the site succinylation level change can be used as a marker for monitoring the development and the progression of lung cancer, the risk of the development and the progression of lung cancer can be predicted, the lung cancer is increased, a novel diagnosis method for diagnosing lung cancer on a molecular level is provided for clinic, and a novel medicine target is provided for treating lung cancer.
The AMPK alpha 1 subunit is a catalytic subunit of AMPK, and is widely distributed in different tissues and organs, activated AMPK alpha 1 can inhibit the expression of metabolism related enzymes (glucose transporter 1, hexokinase 1 and lactate dehydrogenase) related to the Warburg effect, which can lead to the reduction of glucose uptake and lactate level of tumor cells, so that the growth of NSCLC cells is inhibited, after the lysine residue K66 at 266 th site of AMPK alpha 1 is subjected to succinylation modification, charge is changed, the recognition and cleavage of AIF1 by protease are inhibited, the AIF1 cannot perform apoptosis function, intracellular AIF1 resists enzyme digestion, the enzyme activity of AMPK alpha 1 is inhibited, the regulation of autophagy and apoptosis, the regulation of carbohydrate metabolism, the regulation of lipid metabolism, the regulation of protein metabolism, the regulation of mitochondrial function is carried out to promote the growth of lung cancer cells, the oxidative respiration required by the cells is maintained, and the glucose uptake and lactate level of lung cancer cells are improved, so that the succinylation expression level of AMPK alpha 1 can be used as a relevant target for treating lung cancer.
Example 2
Materials, reagents, etc. used in the following examples were obtained commercially, and the quantitative tests in the following examples were performed in triplicate, and the results were averaged, unless otherwise specified.
This example analyzes the level of succinylation modification of the clinical specimen lung cancer tissue ampkα1 at position 266, lysine residue (K266), by immunohistochemistry.
The succinylation level of the 266 st lysine residue of AMPK alpha 1 in cancer tissues and paracancer tissues was detected by using an antibody specifically recognizing succinylation of AMPK alpha 1 at the K266 site, and the tissue samples were human lung cancer tissues, and 85 cases of lung cancer tissues and 85 cases of paracancer tissues were combined.
In the analysis result, the interpretation mode of the original experimental data is as follows:
interpreting the intensity and the positive dyeing rate of cytoplasmic dyeing by AMPK alpha 1 succinylation analysis; cancerous and paracancerous tissues (epithelium) are interpreted separately.
Normalization protocol of raw experimental data:
antibody: ampkα1 succinylated antibody (K266);
staining intensity score: score 0 (negative), score 1 (1+), score 2 (2+), score 3 (3+);
staining positive rate score: 0% -100%;
total score: the "staining intensity score" multiplied by "staining positive rate" (0-300%);
the analysis results were as follows:
1. differential analysis of antibody expression in cancer and paracancerous tissues
Analysis of the AMPKα1 succinylation levels (K266) of 1-1, lung cancer tissue and paracancestral tissue is shown in the following Table:
* Significance statistics (p < 0.05)
FIG. 1 is a schematic diagram showing the expression level of K266 succinylated modified AMPKα1, and in combination with FIG. 1, the expression level of succinylated AMPKa1 protein in lung cancer tissue is significantly higher than that in paracancerous tissue (p < 0.001) according to Mann-Whitney test.
Correlation analysis of 1-2, AMPK alpha 1 succinylation levels and patient prognosis
Referring to FIG. 2, it is understood from the Kaplan-Meier survival analysis result that the succinylated AMPKa1 protein high expression is significantly correlated with the lung cancer prognosis (p < 0.01).
1-3, K266 succinylation modification AMPK alpha 1 to promote lung cancer growth
Referring to FIG. 3, lung cancer cells expressing AMPKα1 and lung cancer A549 cells expressing the 266 th lysine succinylation modification AMPKA1 were inoculated into nude mice, and the breeding animals were bred for 21 days, and the results showed that the average mass of tumor masses of wild-type AMPKA1 was 0.05g, the average mass of tumor masses of K266 succinylation modification AMPKA1 was 0.18g, and the growth rate of the lung cancer cells of K266 succinylation modification AMPKA1 was significantly faster than that of the lung cancer cells expressing AMPKA1, and P < 0.01.
It is apparent that the above examples are given by way of illustration only and are not limiting of the embodiments. Other variations or modifications of the above teachings will be apparent to those of ordinary skill in the art. It is not necessary here nor is it exhaustive of all embodiments. While the obvious variations or modifications which are extended therefrom remain within the scope of the claims of this patent application.

Claims (6)

1. Succinylation modified AMPK alpha 1, characterized in that AMPK alpha 1 is succinylated at lysine residue 266.
2. Use of succinylated modified AMPK alpha 1 as defined in claim 1 for the preparation of a formulation for promoting growth, proliferation and/or migration of a tumour cell or cancer cell, which is a lung cancer cell.
3. Use of succinylated modified AMPK alpha 1 as defined in claim 1 in the preparation of a lung cancer diagnostic reagent or kit.
4. The use of succinylated modified AMPK alpha 1 as defined in claim 1 in the preparation of a lung cancer cell sample.
5. Use of succinylated modified AMPK alpha 1 as defined in claim 1 for the preparation of a reagent or kit for validating succinylation of AMPK alpha 1.
6. A product, characterized in that an active ingredient of the product comprises succinylated modified AMPK α1 as defined in claim 1, and the product has at least one of the following functions (1) to (4):
(1) Predicting the risk of occurrence and development progression of lung cancer; (2) an increase in the number of cells predicted to have lung cancer, poor prognosis; (3) promoting and maintaining lung cancer cell survival and growth; (4) as a target for treating lung cancer.
CN202211116713.5A 2022-09-14 2022-09-14 AMPK alpha 1 succinylation modification and application Active CN115261355B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202211116713.5A CN115261355B (en) 2022-09-14 2022-09-14 AMPK alpha 1 succinylation modification and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202211116713.5A CN115261355B (en) 2022-09-14 2022-09-14 AMPK alpha 1 succinylation modification and application

Publications (2)

Publication Number Publication Date
CN115261355A CN115261355A (en) 2022-11-01
CN115261355B true CN115261355B (en) 2023-07-28

Family

ID=83756334

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202211116713.5A Active CN115261355B (en) 2022-09-14 2022-09-14 AMPK alpha 1 succinylation modification and application

Country Status (1)

Country Link
CN (1) CN115261355B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116879563B (en) * 2023-07-20 2024-05-14 南昌大学 Application of 317 th lysine succinylated modified lactate dehydrogenase C as weak sperm disease development marker or target

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050898A2 (en) * 2002-12-04 2004-06-17 Elixir Pharmaceuticals, Inc. Ampk pathway components
CN103827083A (en) * 2011-08-08 2014-05-28 韩诺生物制药株式会社 N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
CN110403940A (en) * 2019-07-12 2019-11-05 山东省立医院 Application of the succinylation related preparations in regulation mitochondria OCR

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11643691B2 (en) * 2018-04-13 2023-05-09 Duke University Predictive biomarkers for cancer immunotherapy and methods of using same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050898A2 (en) * 2002-12-04 2004-06-17 Elixir Pharmaceuticals, Inc. Ampk pathway components
CN103827083A (en) * 2011-08-08 2014-05-28 韩诺生物制药株式会社 N1-cyclic amine-N5-substituted phenyl biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same
CN110403940A (en) * 2019-07-12 2019-11-05 山东省立医院 Application of the succinylation related preparations in regulation mitochondria OCR

Also Published As

Publication number Publication date
CN115261355A (en) 2022-11-01

Similar Documents

Publication Publication Date Title
Wei et al. The association between cardiorespiratory fitness and impaired fasting glucose and type 2 diabetes mellitus in men
Sugimura et al. Long-term survivorship in lung cancer: a review
Devarbhavi et al. Antituberculosis therapy drug‐induced liver injury and acute liver failure
Freedman et al. Relationships between electrochemical skin conductance and kidney disease in type 2 diabetes
CN115261355B (en) AMPK alpha 1 succinylation modification and application
WO2005098046A3 (en) Methods for the determination of cell specific biomarkers
Meerkerk et al. Sarcopenia measured with handgrip strength and skeletal muscle mass to assess frailty in older patients with head and neck cancer
Brown et al. A randomized phase II dose–response exercise trial among colon cancer survivors: purpose, study design, methods, and recruitment results
Lin et al. Healthy diet is associated with gene expression in blood: the Framingham Heart Study
Gallois et al. Skeletal muscle loss during chemotherapy and its association with survival and systemic treatment toxicity in metastatic colorectal cancer: an AGEO prospective multicenter study
CN107475386B (en) Long-chain non-coding RNA marker for diagnosis and treatment osteosarcoma
TWI798532B (en) Use of kdm5a gene and atrx gene
Izzotti DNA damage and alterations of gene expression in chronic-degenerative diseases.
Germani et al. Histological subclassification of cirrhosis
Rigamonti et al. Transient elastography in the early prediction of progressive recurrent hepatitis C following liver transplantation
Khosroshahi et al. The impact of malnutrition on mortality and complications of hematopoietic stem cell transplantation in patients with acute leukemia
Maguolo et al. Cardiovascular risk factors in children and adolescents with type 1 diabetes mellitus: The role of insulin resistance and associated genetic variants
Kebede et al. Assessment of serum uric acid, urea, and glucose levels and associated factors among breast cancer patients attending a tertiary hospital in bahirdar, ethiopia: a comparative cross-sectional study
CN110400640A (en) A kind of research method of low carbohydrate diet to non-alcoholic fatty liver disease
Prentice Women’s health initiative studies of postmenopausal breast cancer
Udristioiu et al. Relationship between LDH and Mg in Monitoring of Hematological and Non-Hematological Malignant Diseases
Xu et al. Is cigarette smoking an independent risk factor or a cofactor for nonalcoholic fatty liver disease?
CN109979598B (en) By human body18F-FDG PET data analysis tissue DNA hydroxymethyl background and application
Elmahi et al. The Impact of Serum Ferritin on Exfoliated Cells Morphology from Buccal Mucosa among Iron Deficiency Anemia Patients: Morphometric Study
Zhang et al. Research Article Association between the Oxidative Balance Score and Telomere Length from the National Health and Nutrition Examination Survey 1999-2002

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant